DH
Therapeutic Areas
AFT Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Maxigesic® IV | Post-operative pain management | Approved/Commercial |
| Maxigesic® Oral Tablets | Acute pain | Approved/Commercial |
| Maxigesic® Oral Suspension (Pediatric) | Pain and fever in children | Approved/Commercial |
| Maxigesic® Rapid (ODT) | Acute pain | Launched |
| Maxigesic® Intranasal Formulation | Acute pain | Pre-clinical |
Leadership Team at AFT Pharmaceuticals
MM
Mr. Mark Freeman
Chief Financial Officer
DD
Dr. David McIlroy
Head of Research & Development
MM
Mr. Malcom Tubby
Head of Marketing & Sales (NZ)
MS
Mr. Stephen McMillan
Head of International
MA
Ms. Andrea Lillis
Company Secretary & General Counsel
MJ
Mr. John Robson
Non-Executive Chairman
PJ
Prof. John Shaw
Non-Executive Director
MA
Ms. Alison Quesnel
Non-Executive Director